Live
- First Star Outside Milky Way Captured: WOH G64 is 2,000 Times Larger Than the Sun
- Sikkim govt to constitute state Niti Ayog: CM Tamang
- CBI books Rajasthan narcotics inspector for Rs 3 lakh bribe
- Rajasthan bypolls: A tough contest between BJP and Congress
- Albania joins SEPA, paving way for EU integration
- Japanese government approves 250-billion USD economic package to ease price pain
- Six pharma companies to set up their units in Telangana
- The Unstable Events of a 17-Wicket Day in Perth: India vs Australia
- Dutch FM's Israel trip cancelled after Netanyahu's arrest warrant
- UK to increase energy price cap by 1.2 per cent
RLS gets DCGI nod for Corona drug Favipiravir
RLS gets DCGI nod for Corona drug Favipiravir
City-based Raghava Life Sciences Limited (RLS) on Monday said it received Drug Controller General of India (DCGI) approval to manufacture and market bulk drug (API) for Favipiravir which is being widely used for the treatment of Covid-19
Hyderabad: City-based Raghava Life Sciences Limited (RLS) on Monday said it received Drug Controller General of India (DCGI) approval to manufacture and market bulk drug (API) for Favipiravir which is being widely used for the treatment of Covid-19.
RLS Managing Director P Lohit Reddy said that pharma companies such as Lupin, Hetero, Cipla and Sun Pharma recently launched oral pills of favipiravir under their own brands at competitive prices.
"Favipiravir is being widely considered successful in treating Covid patients. The medicine is currently being prescribed to Covid-19 patients with mild to moderate symptoms.
A data from clinical trials involving 150 subjects showed that about 70 per cent of the patients being treated with the drug achieved clinical cure by the fourth day of the study, compared with about 45 per cent in the standard care group," Reddy said.
Advanced stage trials of favipiravir are currently underway in several countries including India. RLS, which also specializes in contract research projects, received approval to supply the active pharmaceutical ingredient (API) of the drug to formulation companies.
